60186-14-3

Basic information

• Product Name: 4-difluoro-3-nitropyridine
• Synonyms: 4-difluoro-3-nitropyridine;2,4-Difluoro-3-nitropyridine
• CAS NO: 60186-14-3
• Molecular Formula: C₅H₂F₂N₂O₂
• Molecular Weight: 160.0783864
• Mol File: 60186-14-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: 6 °C
• Boiling Point: 256.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.555±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -5.60±0.18(Predicted)
• CAS DataBase Reference: 4-difluoro-3-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-difluoro-3-nitropyridine(60186-14-3)
• EPA Substance Registry System: 4-difluoro-3-nitropyridine(60186-14-3)

Safety Data

• Hazardous Substances Data: 60186-14-3(Hazardous Substances Data)

Usage

Description

4-Difluoro-3-nitropyridine is an organic compound characterized by the presence of a pyridine ring with two fluorine atoms at the 4th position and a nitro group at the 3rd position. It is a versatile intermediate in the synthesis of various pharmaceuticals and agrochemicals due to its unique structural features and reactivity.

Uses

Used in Pharmaceutical Industry:
4-Difluoro-3-nitropyridine is used as a key reactant in the synthesis of AMP579, a novel adenosine A1/A2 receptor agonist. 4-difluoro-3-nitropyridine has potential applications in the treatment of various diseases and conditions, such as neuroprotection, inflammation, and cardiovascular disorders, due to its ability to modulate adenosine receptor signaling pathways.
Additionally, 4-difluoro-3-nitropyridine can be utilized in the development of other bioactive molecules and drug candidates, given its reactivity and compatibility with various chemical transformations. Its presence in the molecular structure can impart unique properties and activities, making it a valuable building block in medicinal chemistry and drug discovery efforts.

Upstream product

• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 2751-90-8 tetraphenylphosphonium bromide 

Downstream Products

• 280756-72-1 [3aR-[3aα,4α,6a(R*),6aα]]-6-[4-[[1-[(3-chlorothien-2-yl)methyl]propyl][4-methylbenzenesulfonyl]amino]-3-nitropyrid-2-ylamino] N-ethyl tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-carboxamide 
• 280756-73-2 [3aR-[3aα,4α,6a(R*),6aα]]-6-[4-[[1-[(3-chlorothien-2-yl)methyl]propyl][4-methylbenzenesulfonyl]amino]-3-aminopyrid-2-ylamino] N-ethyl tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-carboxamide 
• 313268-73-4 [3aR-[3aα,4α,6a(R*),6aα]]-6-[7-[[1-[(3-chlorothien-2-yl)methyl]propyl][4-methylbenzenesulfonyl]amino]-3H-imidazo(4,5-b)pyrid-3-yl] N-ethyl tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxole-4-carboxamide 
• 143395-98-6 [1S-[1α,2β,3β,4α(S*)]]-4-[7-[[1-[(3-chlorothien-2-yl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyrid-3-yl] N-ethyl 2,3-dihydroxycyclopentanecarboxamide 
• 280756-71-0 (R)-N-[1-[(3-chlorothien-2-yl)methyl]propyl]-N-(2-fluoro-3-nitropyrid-4-yl)-4-methylbenzenesulfonamide 

Relevant articles and documents

FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided c

Process for preparing N6-substituted adenosine derivatives

This invention is directed to a process for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.

Efficient synthesis of AMP579, a novel Adenosine A1/A2 receptor agonist

-